Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. (NTRA) director and co-founder Jonathan Sheena sold 3,150 common shares across eight reported sale entries on October 21, 2026, at reported per-share prices ranging from $406.5000 to $416.6736. The sales were made under a Rule 10b5-1 trading plan adopted December 12, 2025. The filing also lists 8,250 shares held for beneficiaries of each of the Caraluna 1 Trust and Caraluna 2 Trust; Sheena disclaims beneficial ownership of those trust-held securities.
Natera, Inc. director Jonathan Sheena gave notice of a proposed sale of 9,450 common shares, with an approximate sale date of October 21, 2026. The notice lists an aggregate market value of $3,879,737 and names Charles Schwab & Co., Inc. as broker. It also reports sales during the preceding three months, including 18,064 shares on September 23 for $7,008,972 and 9,150 shares on August 7 for $2,888,325.
Natera, Inc. (NTRA) had 1,500 common shares sold in 12 transactions by Caraluna 1 Trust and Caraluna 2 Trust on October 16, 2026. The sales were made under a Rule 10b5-1 trading plan adopted by director and co-founder Sheena Jonathan on June 11, 2026. The shares were held for trust beneficiaries, and Jonathan disclaims beneficial ownership. A separate direct-holdings entry lists 221,314 common shares following the transactions.
Natera, Inc. executive chairman Matthew Rabinowitz exercised options for 50,000 common shares at $10.41 per share on October 15, 2026, and reported sales of 50,000 shares in 19 transactions. Reported sale prices included weighted averages of $388.3187 per share for 286 shares and $408.2356 per share for 2,000 shares. The sales were effected under a Rule 10b5-1 plan adopted June 12, 2026; the options were fully exercisable, with zero options reported after exercise and an expiration date of June 8, 2027.
Natera, Inc. (NTRA) is identified as the issuer in a notice reporting Matthew Rabinowitz’s proposed sale of 50,000 common shares, with an aggregate market value of $19,737,500.00 and an approximate sale date of October 15, 2026. The sales history also lists three earlier sales labeled 10b5-1 Sales, each for 50,000 shares, on September 11, September 14 and September 15, 2026.
Natera, Inc. (NTRA) Executive Chairman Matthew Rabinowitz made a charitable contribution of 6,000 shares of common stock on October 7, 2026. The transfer was reported as a bona fide gift, not a market sale; he directly held 2,119,394 shares after the transaction.
Natera, Inc. CEO and President Steven Leonard Chapman sold 1,273 shares of common stock on October 1, 2026, at $413.31 per share. The sale was effected under a Rule 10b5-1 trading plan adopted December 11, 2023, and amended on December 2, 2024, and March 5, 2026. Chapman held 96,926 shares directly after the sale.
Solomon Moshkevich, Natera's President, ClinicalDiagnostics, sold 3,000 common shares on October 1, 2026, in three reported sales: 200 shares at a weighted average price of $411.6200, 954 at $413.1066, and 1,846 at $415.0691. The sales were made under a Rule 10b5-1 trading plan adopted November 26, 2024.
Natera, Inc. (NTRA) lists a proposed sale by Officer and Director Steven Leonard Chapman of 1,273 common shares, with an aggregate market value of $526,143.63. Morgan Stanley Smith Barney LLC is identified as broker, and the approximate sale date is October 1, 2026.
Natera, Inc. (NTRA) notice reports that Officer Solomon Moshkevich proposed selling 3,000 common shares through Morgan Stanley Smith Barney, with an approximate sale date of October 1, 2026, and a stated aggregate market value of $1,242,645.30. The notice lists 144,144,170 common shares outstanding and five sales by Moshkevich during the prior three months, dated July 27 through September 2, 2026.